Second selective COX-2 inhibitor receives marketing approval.
Miller
J L
JL
D002986:Clinical Trials as Topic; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000627:therapeutic use*; D017277:Drug Approval; D004412:Dysmenorrhea / Q000188:drug therapy*; D004791:Enzyme Inhibitors; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D007783:Lactones / Q000627:therapeutic use*; D008565:Membrane Proteins; D010003:Osteoarthritis / Q000188:drug therapy*; D010146:Pain / Q000188:drug therapy*; D011451:Prostaglandin-Endoperoxide Synthases / Q000494:pharmacology*; D013450:Sulfones; D014481:United States; D014486:United States Food and Drug Administration
D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D004791:Enzyme Inhibitors; D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases